the aid library

LIST OPTIONS

Filter

2556

Africa CDC Event-based Surveillance Framework: interim version 2018

African Union; Africa CDC Centres for Disease Control and Prevention Africa CDC (2018) CC

Event-based surveillance (EBS) is defined as the organized collection, monitoring, assessment and interpretation of mainly unstructured ad hoc information regarding health events or risks, which may represent an acute risk to health. Both indicator-based and event-based surveillance components serve... more

External Link

Africa CDC: Event based Surveillance Framework

Africa CDC (2018) C_CDC

Download (473)

View PDF (946)

WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis
recommended

World Health Organization WHO (2018) C_WHO

The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.

Download (180)

View PDF (198)

People-centred framework for tuberculosis programme planning and prioritization, User guide

World Health Organization WHO (2019) C_WHO

The aim of the people-centred framework is to help countries to develop fully prioritized and budgeted NSPs based on a culture of making full use of the available data, which are aligned with national planning cycles and which provide the basis for a robust national response that can accelerate prog... more

Download (145)

View PDF (187)

Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence, Rapid Review 22 February 2022
recommended

Pan American Health Organisation PAHO (2022) C_WHO

This document includes the results of a rapid systematic review of current available literature. The information included in this review reflects the evidence as of the date posted in the document. In recognition of the fact that there are numerous ongoing clinical studies, PAHO will periodically up... more

External Link

UNHCR’s mental health and psychosocial support

Meyer, S. UNHCR (2013) C2

A broad range of UNHCR’s key priorities overlap with MHPSS issues – for example, child protection and sexual and gender-based violence [SGBV] prevention and response. Despite all these existent synergies, UNHCR’s current policies and guidelines do not sufficiently link with MHPSS principles.... more

Download (187)

View PDF (223)

Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™)
recommended

World Health Organization WHO (2022) C_WHO

These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc... more

Download (228)

View PDF (273)

Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19

World Health Organization WHO (2022) C_WHO

These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below. This document has been ... more

Download (258)

View PDF (310)

CONSENSUS DOCUMENT FOR MANAGEMENT OF Multiple Myelo

Indian Council of Medical Research (ICMR) (2017) C1

Prepared as an outcome of ICMR Subcommittee on Multiple Myeloma | This consensus document on management of multiple myeloma summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and research questions. It also i... more

External Link

Positive Mental Health, fighting Stigma and promoting resiliency for children and adolescents

Matthew Hodes and Susan Gau IACAPAP (2016) C2

The International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP) aims to promote the mental health and development of children and adolescents worldwide. It seeks to achieve this by contributing to the training and professional development of the child and adole... more

Download (453)

View PDF (271)

Appropriate Use of Medical Resources: Antimicrobial Stewardship Toolkit

American Hospital Association AHA (2019) C2

User GuideThe toolkit is composed of three sections: Hospital and Health System Resources - includes a readiness assessment tool, the starting point in developing or enhancing a successful Antimicrobial Stewardship Program (ASP). The tool, a checklist developed by the CDC, should be shared with se... more

Download (200)

View PDF (197)

Framework for collaborative action on tuberculosis and comorbidities

World Health Organization WHO (2022) C_WHO

Addressing comorbidities and risk factors for TB is a crucial component of Pillar one of the End TB Strategy, which focuses on integrated patient-centred care and prevention, including action on TB and comorbidities. The Framework for collaborative action on TB and comorbidities aims to support coun... more

External Link

Reducing hospital-acquired infections and improving the rational use of antibiotics in a developing country: an effectiveness study

Murni I. K., T. Duke, S. Kinney et al. (2014) C2

Nosocomial infections, or hospital-acquired infec-tions (HAI), are among the most significant causesof morbidity and mortality in healthcare settingsthroughout the world.Prevention of HAIs iscentral to providing high quality and safe health-care, even in settings with limited resources.Transmi... more

Download (554)

View PDF (398)

Management of Diabetes Mellitus-Tuberculosis
recommended

Lin, Y., et al. The Union (2019) C1

1st edition This resource provides practical guidance for front line health workers responsible for the diagnosis, management and care of patients with these two diseases. Published in collaboration with the World Diabetes Foundation

Download (155)

View PDF (204)

Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm (28 October 2021), updated 15 March 2022

World Health Organization WHO (2022) C_WHO

These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below. Th... more

Download (345)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (199)

View PDF (205)

Republic of South Africa: Antimicrobial Resistance National Strategy Framework 2018 – 2024

Departments of Health and Agriculture, Forestry and Fisheries for the Republic of South Africa (2014) C_WHO

The National Department of Health and Department of Agriculture, Forestry and Fisheries have collectively engaged to determine the key interventions that will form the basis for this strategy taking into account the recommendations from the WHO and OIE. The development and implementation of a Natio... more

Download (281)

View PDF (459)

Manual for Health Counselors. The MANAS Program

S. Chatterjee and N. Chowdhary Sangath (2018) CC

This manual is a resource for Health Counselors working in Family Physician Clinics (FPC) as part of the MANAS program. This program is for common mental disorders like depression and anxiety seen in primary health care facilitieslike the FPC; since depression is the common... more

Download (247)

View PDF (258)

Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19: interim guidance, 20 December 2021

World Health Organization WHO (2022) C_WHO

27 September 2022 These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.

Download (581)

View PDF (833)

Evidence of the risks and benefits of vaccinating pregnant women with WHO pre-qualified cholera vaccines during mass campaigns

Global Task Force on Cholera Control (GTFCC) World Health Organisation (WHO) (2016) C_WHO

The technical note from the Global Task Force on Cholera Control (GTFCC) examines the risks and benefits of vaccinating pregnant women with WHO-prequalified oral cholera vaccines (OCVs) during mass vaccination campaigns. It highlights that three WHO-approved vaccines (Dukoral®, Shanchol™, and Euv... more

WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis recommended

Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence, Rapid Review 22 February 2022 recommended

Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) recommended

Management of Diabetes Mellitus-Tuberculosis recommended

WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis
recommended

Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence, Rapid Review 22 February 2022
recommended

Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™)
recommended

Management of Diabetes Mellitus-Tuberculosis
recommended